|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
3006
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
109
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
138
|
May 20, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1294
|
May 18, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
205
|
May 8, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines-Pub
|
|
2
|
192
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
543
|
April 30, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
147
|
April 29, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
505
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
246
|
April 20, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
282
|
April 17, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
155
|
April 14, 2026
|
|
Determination of N-nitroso Caspofungin
|
|
1
|
145
|
March 27, 2026
|
|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
94
|
March 20, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
382
|
March 19, 2026
|
|
Testing of N-nitroso-cinacalcet
|
|
8
|
1244
|
March 14, 2026
|
|
Navigating the complexities in characterization of NDSRIs using advanced analytical techniques-Pub
|
|
2
|
284
|
March 12, 2026
|
|
N-Nitrosodibenzylamine infusion bags
|
|
0
|
133
|
February 27, 2026
|
|
👨💻 Quantitation of N-Nitrosodimethylamine (NDMA) and N-Nitrosophenylephrine (NNPE) in Phenylephrine Hydrochloride (API) by LC-MS/MS
|
|
0
|
467
|
February 7, 2026
|
|
👨💻 N-Nitroso-Propranolol Test Method & Validation Report
|
|
0
|
205
|
February 7, 2026
|
|
👨💻 N-Nitroso-Methylphenidate Test Method and Validation Report
|
|
0
|
194
|
February 7, 2026
|
|
Ames Concordance with the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency with Nitrosamines with Robust Dose-Response Carcinogenicity Data-Pub
|
|
1
|
258
|
February 5, 2026
|
|
Available Tools for Prediction of Potential Degradation Products from Nitrosation Reactions
|
|
4
|
341
|
February 4, 2026
|
|
N-nitroso-rivaroxaban amide
|
|
7
|
2159
|
February 4, 2026
|
|
TGA updated Established acceptable intake for nitrosamines in medicines on 29 January 2026
|
|
0
|
493
|
January 29, 2026
|
|
Nitrosamine Drug Substance-Related Impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon Cytochrome P450-dependend metabolic activation-Pub
|
|
2
|
281
|
January 29, 2026
|
|
Sufentanil Nitroso impurity standard
|
|
8
|
272
|
January 29, 2026
|
|
Nitrosamine Impurities: The Analytical & Regulatory Roadmap (2024-2025)
|
|
0
|
475
|
January 20, 2026
|
|
N-nitrosamides, N-nitrosoureas, Nnitrosoguanidines
|
|
7
|
663
|
December 30, 2025
|
|
Establishing Best Practice for N- Nitrosamine Read-Across and Surrogate Selection
|
|
0
|
185
|
December 22, 2025
|